|Assessment Status||No HTA dossier submitted|
|Indication||Treatment of newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).|
|Rapid review commissioned||03/10/2018|
|Rapid review completed||15/11/2018|
|Rapid review outcome||Full Pharmacoeconomic Assessment Recommended|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.